[Research Progress in Drug Therapy for Bronchopulmonary Dysplasia in Preterm Infants]

Overview

Journal Zhongguo Dang Dai Er Ke Za Zhi

Specialty Pediatrics

Date 2018 Jan 17

PMID 29335086

Citations 1

Authors

Yu-Chen Yang

Jian Mao

Juan Li

Affiliations

Soon will be listed here.

Abstract

Bronchopulmonary dysplasia (BPD) is the most common long-term complication in surviving extremely preterm infants. This may lead to pulmonary hypertension, increase late neonatal mortality, and cause abnormal neural development. There is still controversy over the efficacy, as well as advantages and disadvantages, of drug therapy for BPD in preterm infants. This article reviews the research progress in the drug therapy for BPD.

Citing Articles

[Clinical effect of an additional maintenance dose of caffeine before ventilator weaning in preterm infants with respiratory distress syndrome: a prospective randomized controlled trial].

Yao L, Lin X, Huang J, Tang L Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(1):31-36.

PMID: 33476534 PMC: 7818149.

References

Shinwell E, Portnov I, Meerpohl J, Karen T, Bassler D . Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics. 2016; 138(6). DOI: 10.1542/peds.2016-2511. View

de Visser Y, Walther F, Laghmani E, Boersma H, van der Laarse A, Wagenaar G . Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res. 2009; 10:30. PMC: 2681457. DOI: 10.1186/1465-9921-10-30. View

Clouse B, Jadcherla S, Slaughter J . Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions. PLoS One. 2016; 11(2):e0148188. PMC: 4740433. DOI: 10.1371/journal.pone.0148188. View

Collaco J, Romer L, Stuart B, Coulson J, Everett A, Lawson E . Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol. 2012; 47(11):1042-53. PMC: 3963167. DOI: 10.1002/ppul.22609. View

Yeh T, Chen C, Wu S, Husan Z, Li T, Hsieh W . Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2015; 193(1):86-95. DOI: 10.1164/rccm.201505-0861OC. View

Darlow B, Graham P, Rojas-Reyes M . Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2016; (8):CD000501. PMC: 7038719. DOI: 10.1002/14651858.CD000501.pub4. View

Laughon M . Vitamin A shortage and risk of bronchopulmonary dysplasia. JAMA Pediatr. 2014; 168(11):995-6. DOI: 10.1001/jamapediatrics.2014.1416. View

Venkataraman R, Kamaluddeen M, Hasan S, Robertson H, Lodha A . Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Pediatr Pulmonol. 2017; 52(7):968-975. DOI: 10.1002/ppul.23680. View

Maas C, Poets C, Bassler D . Survey of practices regarding utilization of inhaled steroids in 223 German neonatal units. Neonatology. 2010; 98(4):404-8. DOI: 10.1159/000316978. View

10.

Onland W, Offringa M, van Kaam A . Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2012; (4):CD002311. DOI: 10.1002/14651858.CD002311.pub3. View

11.

Nagatomo T, Jimenez J, Richter J, De Baere S, Vanoirbeek J, Naulaers G . Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits. Neonatology. 2016; 109(4):274-81. DOI: 10.1159/000442937. View

12.

Fehrholz M, Glaser K, Speer C, Seidenspinner S, Ottensmeier B, Kunzmann S . Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts. Respir Res. 2017; 18(1):51. PMC: 5363056. DOI: 10.1186/s12931-017-0535-8. View

13.

Abman S, Hansmann G, Archer S, Ivy D, Adatia I, Chung W . Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015; 132(21):2037-99. DOI: 10.1161/CIR.0000000000000329. View

14.

Onland W, De Jaegere A, Offringa M, van Kaam A . Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 1:CD010941. PMC: 6464844. DOI: 10.1002/14651858.CD010941.pub2. View

15.

Ambalavanan N, Tyson J, Kennedy K, Hansen N, Vohr B, Wright L . Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005; 115(3):e249-54. DOI: 10.1542/peds.2004-1812. View

16.

Slaughter J, Stenger M, Reagan P, Jadcherla S . Inhaled bronchodilator use for infants with bronchopulmonary dysplasia. J Perinatol. 2014; 35(1):61-6. PMC: 4281278. DOI: 10.1038/jp.2014.141. View

17.

Iyengar A, Davis J . Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. Front Pharmacol. 2015; 6:12. PMC: 4329808. DOI: 10.3389/fphar.2015.00012. View

18.

Shah V, Ohlsson A, Halliday H, Dunn M . Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2012; (5):CD001969. DOI: 10.1002/14651858.CD001969.pub3. View

19.

Lista G, Fabbri L, Polackova R, Kiechl-Kohlendorfer U, Papagaroufalis K, Saenz P . The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study. Neonatology. 2016; 109(3):221-7. DOI: 10.1159/000442813. View

20.

Van Meurs K, Wright L, Ehrenkranz R, Lemons J, Ball M, Poole W . Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005; 353(1):13-22. DOI: 10.1056/NEJMoa043927. View